TAO Synergies Inc.
TAOX evidence brief
What we can confirm
- BioSniper Score:
- 5.6 / 10
- Market Cap:
- $34.2M
- Lead Asset:
- bryostatin-1 (Phase 1)
What it means
What to watch
Prepared research question
What matters most for TAOX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · TAOX
TAO Synergies Inc. (TAOX) is a biopharmaceutical company focused on developing Bryostatin-1 for neurodegenerative diseases, with a cash-intensive operating model and ongoing capital needs.
Key risk: Cash burn and runway
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$34.2M
Cash Runway
—
Lead Asset
bryostatin-1 (Phase 1)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate for TAO Synergies Inc..
TAO Synergies Inc. (TAOX) is a biopharmaceutical company focused on developing Bryostatin-1 for neurodegenerative diseases, with a cash-intensive operating model and ongoing capital needs.
- Cash & equivalents of $2.4M as of 2026-06-30 [sec].
- Total revenue of $0.1M and net income of -$9.3M as of 2026-06-30 [sec].
- Shareholders' equity of $12.7M as of 2026-06-30 [sec].
- Working capital decreased from $23.6M (Dec 2025) to $19.6M (Jun 2026) due to operating expenses and digital asset declines [sec_mda · as of 2026-08-13].
- Company expects current cash and digital assets (~$18.8M) to fund operations for at least 12 months from Aug 2026 [sec_mda · as of 2026-08-13].
What works
- Management projects current liquidity (cash + digital assets ~$18.8M) will sustain operations for at least 12 months from August 2026 [sec_mda · as of 2026-08-13].
- The company has a clinical-stage asset (Bryostatin-1) targeting Alzheimer's disease and other neurodegenerative conditions, with ongoing development [sec_mda · as of 2025-03-27].
- Working capital increased by $5.6M in Q1 2026, partly from digital asset appreciation and warrant issuances [sec_mda · as of 2026-05-13].
What to weigh
- The company has incurred negative cash flows from operations since inception and reported a net loss of $9.3M for the six months ended June 30, 2026 [sec] [sec_mda · as of 2026-08-13].
- Working capital declined by $4.0M in the first half of 2026, driven by $2.9M in operating expenses and a $1.1M decrease in digital assets [sec_mda · as of 2026-08-13].
- Additional capital may not be available on favorable terms, and if unavailable could materially harm the business [sec_mda · as of 2026-08-13].
- The company terminated its collaboration with the Cleveland Clinic for a Phase 1 MS trial in December 2024, after incurring ~$528,000 in costs [sec_mda · as of 2025-03-27].
From the filings
Quoted directly from source documents.
Working capital decrease in first half 2026
“As of June 30, 2026, we had working capital of $19,585,415 as compared to working capital of $23,564,919 as of December 31, 2025. The $3,979,504 decrease in working capital was primarily attributable to operating expenses of approximately $2.9 million, decrease in digital assets of approximately $1.1 million”
SEC MD&A · August 13, 2026
Cash runway projection
“We expect that our current cash and cash equivalents and digital assets of approximately $18.8 million will be sufficient to support our projected operating requirements for at least the next 12 months from the date of this Quarterly Report on Form 10-Q”
SEC MD&A · August 13, 2026
Risks & what to watch (4)›
Key risks
- Cash burn and runway — Net loss of $9.3M in H1 2026; working capital declining; company relies on digital assets for liquidity [sec] [sec_mda · as of 2026-08-13].
- Financing uncertainty — Additional capital may not be available on favorable terms; if unavailable, could materially harm business [sec_mda · as of 2026-08-13].
- Clinical pipeline dependency — Single lead candidate Bryostatin-1; MS trial collaboration terminated Dec 2024 [sec_mda · as of 2025-03-27].
- Digital asset volatility — Working capital affected by changes in digital asset values (e.g., $1.1M decrease in H1 2026) [sec_mda · as of 2026-08-13].
What to watch
- Cash and digital asset levels over next 12 months to assess runway [sec_mda · as of 2026-08-13].
- Any new financing, partnership, or licensing deals to address capital needs [sec_mda · as of 2026-08-13].
- Clinical progress of Bryostatin-1 in Alzheimer's or other neurodegenerative indications [sec_mda · as of 2025-03-27].
- Changes in digital asset valuations that impact working capital [sec_mda · as of 2026-08-13].
Sources: SEC MD&A · Generated September 25, 2026 · How we verify sources →
Run TAO Synergies Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available TAO Synergies Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.30 · 0% dilution
Lead: Phase 1
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
25
Total value held
$2.7M
| Holder | Shares | Value |
|---|---|---|
| renaissance technologies llc | 101,800 | $579K |
| geode capital management, llc | 88,644 | $505K |
| vanguard capital management llc | 79,369 | $452K |
| vanguard fiduciary trust co | 45,432 | $259K |
| summit financial, llc | 43,275 | $246K |
| morgan stanley | 24,359 | $139K |
| blackrock, inc. | 19,753 | $112K |
| state street corp | 19,300 | $110K |
| dimensional fund advisors lp | 12,619 | $72K |
| northern trust corp | 12,126 | $69K |
Showing top 10 of 25 institutional holders of TAO Synergies Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 13, 2026- % of float
- 8.6%
- Days to cover
- 3.3
- Shares short
- 627,443
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
TAOX short interestGovernance
Frequently asked questions
What is the AI investment thesis for TAO Synergies Inc.?
TAO Synergies Inc. (TAOX) is a biopharmaceutical company focused on developing Bryostatin-1 for neurodegenerative diseases, with a cash-intensive operating model and ongoing capital needs.
What is TAO Synergies Inc.'s lead drug candidate?
TAO Synergies Inc.'s most advanced tracked candidate is bryostatin-1 (Phase 1) for Multiple Sclerosis.
Who is the CEO of TAO Synergies Inc.?
Parkfield Funding is the chief executive officer of TAO Synergies Inc. (TAOX).
Where is TAO Synergies Inc. headquartered?
TAO Synergies Inc. (TAOX) is headquartered in New York, NY, United States.
What therapeutic areas does TAO Synergies Inc. focus on?
TAO Synergies Inc. develops therapies across Neurology, Immunology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.